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Abstract
AIM
To determine the influence of the construction design 
over the biological component’s performance in an 
experimental bio-artificial liver (BAL) device.
METHODS
Two BAL models for liver microorgans (LMOs) were 
constructed. First, we constructed a cylindrical BAL and 
tested it without the biological component to establish 
its correct functioning. Samples of blood and biological 
compartment (BC) fluid were taken after 0, 60, and 
120 min of perfusion. Osmolality, hematocrit, ammonia 
and glucose concentrations, lactate dehydrogenase 
(LDH) release (as a LMO viability parameter), and 
oxygen consumption and ammonia metabolizing capacity 
(as LMO functionality parameters) were determined. 
CPSI and OTC gene expression and function were 
measured. The second BAL, a “flat bottom” model, was 
constructed using a 25 cm2 culture flask while main-
taining all other components between the models. The 
BC of both BALs had the same capacity (approximately 
50 cm3) and both were manipulated with the same 
perfusion system. The performances of the two BALs 
were compared to show the influence of architecture.
RESULTS
The cylindrical BAL showed a good exchange of 
fluids and metabolites between blood and the BC, 
reflected by the matching of osmolalities, and glucose 
and ammonia concentration ratios after 120 min of 
perfusion. No hemoconcentration was detected, the 
hematocrit levels remained stable during the whole 
study, and the minimal percentage of hemolysis (0.65% 
± 0.10%) observed was due to the action of the 
peristaltic pump. When LMOs were used as biological 
component of this BAL they showed similar values to 
the ones obtained in a Normothermic Reoxygenation 
System (NRS) for almost all the parameters assayed. 
After 120 min, the results obtained were: LDH release 
(%): 14.7 ± 3.1 in the BAL and 15.5 ± 3.2 in the NRS 
(n  = 6); oxygen consumption (µmol/min·g wet tissue): 
1.16 ± 0.21 in the BAL and 0.84 ± 0.15 in the NRS (n 
= 6); relative expression of Cps1  and Otc : 0.63 ± 0.12 
and 0.67 ± 0.20, respectively, in the BAL, and 0.86 ± 
0.10 and 0.82 ± 0.07, respectively, in the NRS (n  = 3); 
enzymatic activity of CPSI and OTC (U/g wet tissue): 
3.03 ± 0.86 and 222.0 ± 23.5, respectively, in the 
BAL, and 3.12 ± 0.73 and 228.8 ± 32.8, respectively, 
in the NRS (n  = 3). In spite of these similarities, LMOs 
as a biological component of the cylindrical BAL were 
not able to detoxify ammonia at a significant level 
(not detected vs  35.1% ± 7.0% of the initial 1 mM 
NH4+ dose in NRS, n  = 6). Therefore, we built a second 
BAL with an entirely different design that offers a flat 
base BC. When LMOs were placed in this “flat bottom” 
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device they were able to detoxify 49.3% ± 8.8% of the 
initial ammonia overload after 120 min of perfusion (n 
= 6), with a detoxification capacity of 13.2 ± 2.2 µmol/
g wet tissue.
CONCLUSION
In this work, we demonstrate the importance of adapt-
ing the BAL architecture to the biological component 
characteristics to obtain an adequate BAL performance.
Key words: Bio-artificial liver; Ammonia detoxification; 
Device design; Ornithine Transcarbamylase; Rat liver 
microorgans; Carbamyl Phosphate Synthetase Ⅰ
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This work describes the adaptation of a 
simplified bio-artificial liver (BAL) prototype to make 
it suitable to house rat liver microorgans (LMOs) as 
a biological component, and the evaluation of the 
performance in this new model. We demonstrate that 
the modification in the design of the artificial parts 
employed allows a good performance of LMOs, thus 
showing the importance of architecture and model 
configuration on the design of these devices. Besides its 
application as BAL, this mini bioreactor could serve as 
a suitable laboratory tool to evaluate the behavior and 
functionality of LMOs subjected to different incubation 
conditions due to its simple design and the utilization of 
standard materials.
Pizarro MD, Mamprin ME, Daurelio LD, Rodriguez JV, 
Mediavilla MG. Experimental bio-artificial liver: Importance of 
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INTRODUCTION
Bio-artificial liver (BAL) devices are extracorporeal 
systems that contain functional hepatic tissue or cells 
(the biological component) seeded into a man-made 
bioreactor (the artificial component) and separated 
from blood flow by semipermeable membranes[1]. The 
aim of these devices is to fulfill the necessary hepatic 
functions to keep patients with hepatic failure stabilized 
until the regeneration of their own livers or until the 
appearance of a compatible donor[1,2].
Though the majority of liver functions are performed 
by hepatocytes, the other hepatic cellular types (Kupffer, 
Pit, stellate or Ito, and sinusoidal epithelial cells) are also 
involved and exert some influence over the different 
functions in vivo[2]. Therefore, we became interested in 
studying a biological component possessing all these 
different liver constituent cells in search of a better 
performance of our BAL prototype with respect to a 
previous one designed in our laboratory to house isolated 
hepatocytes[3]. In this sense, liver microorgans (LMOs) 
are an appropriate choice mostly because they are 
thin slices of tissue that keep the liver structure and its 
physiological characteristics and allow a good exchange 
of substances with the surrounding liquid and gaseous 
environment[4,5].
Ammonia elimination from the blood of patients 
with liver failure is a key metabolic reaction that 
any biological component of an efficient BAL should 
accomplish in light of the correlation existing between 
this metabolite accumulation and the progression of 
hepatic failure[3,6]. Nonetheless, etiology of hyperammo-
nemia can also be from non-hepatic situations, including 
sepsis[7,8], urea cycle inborn disorders[9], complications in 
a hepatic transplantation setting[10], complications from 
cirrhosis[11,12], and urinary tract infections[13]. Hyperammo-
nemia should be quickly treated to avoid brain damage 
or even death, and simple hemofiltration is sometimes 
not sufficient to cope with it[10,11]. In this context, a 
device capable of efficiently detoxifying ammonia could 
be useful to ameliorate the condition of the patient. Also, 
it could be utilized in the non-hepatic situations until 
the origin of the complication can be determined and 
controlled[6].
When studying ammonia detoxification function 
displayed by LMOs, we found that these tissue slices 
had excellent performance when incubated in su-
spension in a shaker. This simple system was called 
the Normothermic Reoxygenation System (NRS)[14]. 
Surprisingly, they completely lost this detoxifying ca-
pacity in the BAL device when the blood was overloaded 
with ammonia.
In our laboratory we had previously designed a 
BAL consisting of a cylindrical shaped device to house 
isolated rat hepatocytes as the biological component[4]. 
This system showed a good performance and allowed 
the maintenance of adequate viability and functionality 
of fresh hepatocyte suspensions, and successfully 
fulfilling different in vitro tests that constitute the first 
step in the development of any BAL system[4]. In 
this work, we present the results obtained when we 
enlarged this original prototype to allow accommodation 
to the bulkier LMOs, hypothesizing that this was a 
straightforward path in the design. However, we 
showed that the LMOs were unable to detoxify NH4+, 
and therefore had to redesign the artificial component 
receptacle to make it suitable to this biological com-
ponent. To the best of our knowledge, this is the first 
report that evaluates such an essential issue and is 
valuable information for scientists studying this field of 
research.
MATERIALS AND METHODS
Experimental design
Figure 1 summarizes the path followed to develop a 
BAL prototype suitable for using LMOs as the biological 
721 October 27, 2018|Volume 10|Issue 10|WJH|www.wjgnet.com
component. Step 1: Evaluation of LMO inherent per-
formance, mainly regarding ammonia detoxification 
capacity in the NRS[5] (Figure 2A); Step 2: Adaptation 
of the BAL, originally designed for hepatocytes[3], to 
house LMOs on its biological compartment (BC) (Figure 
2B). Testing of this prototype without any biological 
component establishes its correct functioning. Testing 
of this prototype with LMOs as biological component 
to establish its performance as BAL, especially in 
relation to ammonia detoxification. Comparison with 
the results obtained in the NRS; Step 3: Due to the 
failure of LMOs to detoxify ammonia in the cylindrical 
BAL (in comparison with NRS): development of a 
“flat bottom” BAL (Figure 2C). Testing with LMOs as a 
biological component to determine the influence of the 
BAL configuration and design over the LMO ammonia 
detoxification capacity. Other parameters remained 
similar to the values encountered for the cylindrical 
BAL and were already published[15].
LMO obtainment
LMOs were obtained from livers of 60-day-old male 
Wistar rats with a weight of 250-300 g. Animals were 
given a fourteen day adaptation period to get used to 
the experimental laboratory environment, during which 
they could access standard rodent laboratory food 
and water ad libitum. Rats received care according 
to the principles and recommendations given by the 
National Academy of Sciences (Argentina). The School 
of Biochemical and Pharmaceutical Sciences Institu-
tional Animal Care and Use Committee (Universidad 
Nacional de Rosario, Res No. 139/2011) approved all 
experimental procedures.
Rats were anesthetized (chloral hydrate, 500 
mg/kg body weight, i.p.) and the liver was surgically 
removed. The right medial lobe was cut into blocks 
and LMOs were manually obtained from these blocks 
as thin slices (thickness: 338 ± 27 µm, n = 25), 
using a disposable microtome blade. We did all the 
manipulations over an ice-cooled cutting device to 
reduce liver deterioration, and on top of a piece of 
filter paper to avoid tissue slippage and ensure the 
accurate cutting of LMOs[14]. After slicing, LMOs were 
placed in KH-Base (KHB) solution (KHB, Table 1) and 
were pre-incubated for 15 min before loading into the 
NRS or the BAL prototype. The different KH solution 
compositions are shown in Table 1. KHB media was 
used for the LMO obtaining procedure and during the 
pre-incubation period.
LMOs have been characterized regarding histology, 
water content, and viability (published results[5,14]). 
They were weighted for normalization of results and 
their weights were 0.070 ± 0.020 g (n = 25), showing 
size consistency.
NRS
To evaluate the biological component inherent per-
formance before introducing it into our BAL, we 
Pizarro MD et al . Bio-artificial liver design and performance correlation
tested LMOs in a NRS (Figure 2A). In the NRS, they 
were maintained in Krebs-Henseleit (KH) solution 
at 37 ℃ under carbogen atmosphere (95% O2: 5% 
CO2) using a six-well culture plate for 120 min[5]. To 
determine LMO NH4+ metabolizing capability, we added 
an ammonia overload (1 mmol/L approximate NH4+ 
final concentration[16]) to KH-ammonia solution (KHA, 
Table 1) from a concentrated ammonium chloride 
solution (approximate concentration: 350 mmol/L). 
This ammonia overload is far in excess of the level of 
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this metabolite encountered in plasma of patients with 
liver failure (approximately 0.2 mmol/L). We chose 
this condition of work to challenge LMOs because 
they are supposed to deal with continuously infused 
plasma when applied to animal models of hepatic 
failure or patients in the future[16–18]. The exact amount 
of ammonia in KHA solution was then determined, as 
explained later in this section.
LMO disposition in the NRS is shown in Figure 
2A. Two LMOs were placed on each well with 5 mL 
Figure 1  Schematic representation of the steps followed to arrive to the design of a “flat -bottom” bio-artificial liver device suitable to support the 
appropriate performance of liver microorgans as the biological component. Liver microorgans (LMOs) were obtained from Wistar rat livers: (1) Evaluation of 
LMO performance parameters in Normothermic Reoxygenation System; (2) Evaluation of LMO performance in cylindrical bio-artificial liver (BAL) and finding that they 
were unable to detoxify an ammonia overload in the test blood; (3) Evaluation of LMO performance in the newly designed “flat -bottom” BAL that proved suitable to 
support ammonia detoxification function. LMO: Liver microorgan; NRS: Normothermic Reoxygenation System; BAL: Bio-artificial liver.
Figure 2  Devices used to analyze liver microorgan performance. A: Liver microorgan (LMO) disposition in the Normothermic Reoxygenation System (NRS).; B: 
Cylindrical shaped bio-artificial liver (BAL).; C: “Flat bottom” shaped BAL.; D: Perfusion system components. BC: Biological compartment; Lp: LMO loading port; Ap 1 
and 2: Biological compartment access ports; Bsp: Blood sampling port; O2/CO2: Carbogen supply; Ox: Silicone oxygenating tube.
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Table 1  Composition of the different Krebs-Henseleit 
solution used
of KHA solution plus the ammonia overload, and the 
plate was then introduced in a Dubnoff metabolic 
shaker maintained at 37 ℃ and stirred at 60 cycles/
min. Samples of tissue and the bathing solution were 
taken after 0, 60, and 120 min to evaluate lactate 
dehydrogenase (LDH) release, oxygen consumption, 
and ammonia metabolism[5]. This system is intended 
to evaluate the biological component performance and 
condition per se in a simpler and less stressing manner 
than in the BAL device.
The cylindrical shaped BAL designed to house LMOs as 
biological component
The device designed for hepatocytes[4] was modified 
to use LMOs as biological component (Figure 2B). It 
was constructed with a cylindrical plastic cartridge 
that contained 120 to 140 hollow fibers (PolyamixTM, 
GAMBRO®) assembled to the ends of the cartridge by 
two Y-connectors (Nalgene, # 6152–0375) connected 
to S/P silicone tubes (6.4 mm i.d., 11.2 mm o.d., and 
2.4 mm wall). Two Teflon large catheters (14 gauge, 
2 mm i.d.) and an oxygenator (Ox) made of oxygen 
permeable tube (silicone tubing, 0.078 in. i.d., 0.125 
in. o.d.; cat. No. T5715-9, Baxter Healthcare Corp., 
Deerfield, IL, United States) were assembled through 
the Y-connectors. LMOs were seeded through an 
access port (Lp, Figure 2B) in the space outside the 
fibers (BC capacity: approximately 50 cm3), while ram 
blood (obtained from animals in the animal house 
facility of our school) circulated along the inner space 
of the fibers (the blood compartment).
The “flat bottom” BAL to house LMOs as biological 
component
We constructed a device with a flat base BC using a 
standard 25 cm2 culture flask[15] as shown in Figure 2C. 
The culture flask was adapted introducing a Y-shape 
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connector (Nalgene, # 6152–0375) onto its tap and a 
plain connector (S/P silicone tube, 6.4 mm i.d., 11.2 
mm o.d., and 2.4 mm wall) on one side, to assemble 
the 140 hollow fibers (PolyamixTM, GAMBRO®). The loading 
port (Lp) was introduced on its top surface and the 
oxygenating tube (Ox) (silicone tubing, 0.078 in. i.d., 
0.125 in. o.d.; cat. no. T5715-9, Baxter Healthcare Corp., 
Deerfield, IL, United States) access the BC through the 
free branch of the Y-connector. Both prototypes of BALs 
were tested using the perfusion system (Figure 2D). 
The peristaltic pump ensured ram blood recirculation 
from its reservoir passing through a clot filter/bubble 
trap before entering the hollow fibers. The perfusion 
system was kept at 37 ℃ by the thermostatic bath.
System operation protocol
First of all, a sample of ram blood (basal blood) was 
taken before adding the ammonia overload and filling 
the blood perfusion system by the aid of a peristaltic 
pump (blood volume: approximately 35 mL). The BC 
was then filled with KHA alone (to test the bioreactor 
performance) or with KHA plus 1 g of LMO. Samples 
of blood and BC fluid were taken after 0, 60, and 120 
min of perfusion to assay the different parameters 
mentioned below. Blood samples were centrifuged at 
12000 × g for 3 min in a mini spin centrifuge.
During the experiments (BAL runs), the device 
was operated in horizontal position, immersed in the 
Dubnoff shaker bath at 37 ℃ stirred at 60 cycles/
min. Carbogen gas pressure was kept at 85 mm Hg 
to introduce oxygen in the BC media via the silicone 
tube oxygenator, and in this way pH was maintained 
at 7.40 ± 0.10, which was controlled throughout the 
run. The blood maintained proper oxygenation, and its 
recirculation flow rate was maintained at 9 mL/min.
All the devices designed were subjected to two 
different types of studies: (1) without any biological 
component, to establish the adequate functioning 
of the device and the perfusion system[4]; and (2) 
with biological component, to determine if the chosen 
biological component could accomplish ammonia 
detoxification.
Study of system performance
In experiments without LMOs, we first checked the 
correct system functioning by evaluating the following 
parameters: (1) hematocrit of blood samples after 
centrifugation (10000 × g for 3 min, Rolco CH24 
centrifuge), as the percentage of volume that red cells 
represent from the total (blood cells + plasma). It was 
used to evaluate fluid exchange and the occurrence of 
hemolysis during perfusion; (2) osmolality of plasma 
and extra-fiber fluid was determined with a freezing 
point osmometer (Osmomat 030 Gonotec, GmbH, 
Berlin, Germany) to check the proper passage of fluids 
through the fiber walls; and (3) glucose and ammonia 
concentrations were assessed as described below 
Components KHB solution KHA solution 
NaCl 114 mmol/L 114 mmol/L
KH2PO4 1.2 mmol/L  1.2 mmol/L
KCl 4.8 mmol/L  4.8 mmol/L
MgSO4 1.2 mmol/L  1.2 mmol/L
CaCl2 1.5 mmol/L  1.5 mmol/L
HEPES  10 mmol/L   10 mmol/L
NaHCO3  25 mmol/L   25 mmol/L
Glucose  25 mmol/L   25 mmol/L
Allopurinol    1 mmol/L     1 mmol/L
Fructose    5 mmol/L     5 mmol/L
Glycine -     3 mmol/L
Adenosine -    10 µmol/L
Ornithine -     6 mmol/L
Sodium lactate -   10 mmol/L
pH 7.4 7.4
mOsm/kg H2O 293 ± 6 (n = 10) 328 ± 5 (n = 10)
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; mOsm/kg 
H2O: Osmolality; KHB: KH-Base solution; KHA: KH-ammonia solution.
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and their mass balance was calculated to monitor the 
adequate exchange of metabolites between blood and 
the BC in the device.
Hemolysis assessment
The quantity of hemoglobin in plasma samples obtained 
after 0, 60, and 120 min of perfusion was assessed 
using the oxyhemoglobin method as previously desc-
ribed[19]. The equation proposed by Arnaud et al[20] was 
then used to calculate hemolysis percentage as follows:
Hemolysis (%) = 100 × [(HbS × (1 - Ht))/HbT]
where HbS represents the sample hemoglobin contents, 
in g/100 mL; HbT is the total hemoglobin content 
determined in whole blood, and Ht represents the 
respective hematocrit value.
Glucose level determination
This parameter was assessed with a commercially 
available kit (“Glicemia Enzimática AA”, Wiener 
Laboratories, Rosario, Argentina), as instructed in the 
information leaflet.
LDH release quantification
We used LDH release as a LMO viability parameter. 
This enzyme activity was determined in the KH 
incubation solution and in the liver slices as previously 
described[21]. Results are shown as the percentage 
of the total enzyme activity released to the bathing 
media.
Ammonia level assessment
Samples were stored in liquid nitrogen until ammonia 
quantification was done using the enzymatic method 
described by van Anken[22]. The reaction media (0.8 
mL) was composed of 66.7 mmol/L phosphate buffer, 
pH = 8.30, 0.14 mmol/L NADPH, 6.5 mmol/L sodium 
α-ketoglutarate, 2.5 mmol/L ADP, and 120 UI/mL 
glutamate dehydrogenase (cat. #G2626, Sigma 
Aldrich, St. Louis, MO, United States).
In the BAL, ammonia mass balance was calculated 
using the equations described next:
QB,t = ([A]B,t × VB,t) – ([A]B,Bas × VB,t)
QBC,t = ([A]BC,t × VBC,t) - ([A]BC,Bas × VBC,t)
QT,t = QB,t + QBC,t
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where: QB,t and QBC,t are the ammonia mass in blood 
and the BC solution at time t, respectively; [A]B,t and 
[A]BC,t represent respective ammonia concentrations in 
blood and BC fluid; VB,t and VBC,t are, respectively, the 
volumes of blood and the BC fluid at each time, and 
QT,t is the total ammonia mass at the different assayed 
times.
Then, we calculated the percentage of ammonia 
initial dose metabolized at each time with the sub-
sequent equation:
Initial Dose Detoxified (%) = 100 – [QT,t × 100/ QT,0]
Also, we estimated the µmol of ammonia detoxified 
per gram of LMO as follows:
Ammonia Detoxification (µmol/g wet tissue) = (QT,0 – 
QT,t)/ PT
where PT represents the mass of LMOs in grams.
In the case of the NRS, ammonia concentration 
was determined in the LMO bathing solution and the 
equations applied were:
Initial Dose Detoxified (%) = 100 – [(Qt × 100)/ Qi]
Ammonia Detoxification (µmol/g wet tissue) = (Qi – 
Qt)/ PT
where Qi and Qt represent the amount of ammonia 
measured at the beginning of the experiments and 
after t minutes, respectively, and PT is the total weight 
of LMOs in grams.
Cps1 and Otc expression analysis
As part of the LMO ammonia metabolism study, we 
determined the mRNA and activity levels of Carbamyl 
Phosphate Synthetase Ⅰ (CPSI) and Ornithine Trans-
carbamylase (OTC) that catalyze the first and second 
steps of the urea cycle, respectively.
Total RNA extractions were performed using 
TriReagentTM (Sigma Chem. Co., St. Louis, United 
State) and following the instructions provided by the 
manufacturer. We carried out reverse transcription 
and semi-quantitative PCR as previously described[23]. 
In Table 2, the base sequences of the primers used 
for the study of each gene expression are listed. We 
applied the 2-ΔΔCT method to obtain relative expression, 
using Glyceraldehyde Phosphate Dehydrogenase 
(Gapdh), β-Actin (Actb) and rRNA 18S (Rn18S) as 
reporter mRNAs to normalize the values. Each sample 
was analyzed in triplicate, and its template cDNA initial 
Primers Fragment size Genbank access number
Cps1 5’-ATCTGAGGAAGGAGCTGTCT-3’ (sense)
Cps1 5’-AAAACCACTTGTCAATGGAT-3’ (anti-sense)
120 bp NM_017072
Otc 5’-ATGACAGATGCAGTGTTAGC-3’ (sense)
Otc 5’-CAGGATCTGGATAGGATGAT-3’ (anti-sense)
120 bp NM_013078
Actb 5’-CAACCTTCTTGCCAGCTCCTC-3’ (sense)
Actb 5’-GACGAGCGCAGCGATATC-3’ (anti-sense)
  79 bp NM_031144.2
Rn18S 5’-TAACCCGTTGAACCCCATT-3’ (sense)
Rn18S 5’-CCATCCAATCGGTAGTAGCG-3’ (anti-sense)
150 bp X01117
Gapdh 5’-CCATCACCATCTTCCAGGAG-3’ (sense)
Gapdh 5’-CCTGCTTCACCACCTTCTTG-3’ (anti-sense)
576 bp NM_017008.4
Table 2  Sequences of the primers employed
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quantity was expressed relative to a reference sample, 
considered 1X. This reference sample was taken at time 
0.
CPSI and OTC enzymatic activity determination
To determine CPSI activity we performed the Pierson’s 
colorimetric test[24] that involves the reaction of carbamyl 
phosphate and hydroxylamine to obtain hydroxyurea. 
An enhanced colorimetric test for ureido compounds 
allows the quantification of the hydroxyurea produced 
due to the chromophore absorbance measurement at 
458 nm. CPSI activity is expressed as U/g of wet tissue, 
being U the µmoles of carbamyl phosphate produced 
per minute at 37 ℃.
OTC activity was measured with the method desc-
ribed by Ceriotti[25] as the rate of citrulline formation 
from ornithine and carbamyl phosphate is catalyzed 
by OTC. The quantity of citrulline produced was de-
termined by the diacetyl monoxime-antipyrine reaction 
and OTC activity was also expressed as U/g of wet 
tissue, where U represents the µmoles of citrulline 
synthesized per minute at 37 ℃.
Oxygen consumption
Samples of LMOs were taken at different times (0, 
60, and 120 min) from the NRS or the BAL prototype 
and were put into a thermostized oxygen electrode 
chamber constructed in our laboratory, filled with 
respiration media (KH plus 10 mmol/L HEPES and 
2 mmol/Lm pyruvate, pH = 7.40 at 36 ℃)[14]. The 
oxygen levels in the incubation media were measured 
using a Clark-type oxygen electrode (YSI 5300, Yellow 
Spring, OH, United States). After a 2 min stabilization 
period, the endogenous respiration rate was recorded 
and calculated over a 5 min period. Results are 
expressed as µmol O2/min/g wet tissue[14].
Statistical analysis
Results are expressed as mean ± SD. Data was 
analyzed using one-way or multifactor analysis of 
variance with Scheffe’s multiple range tests as post-
test. Differences between means were considered 
statistically significant when P ≤ 0.05. Dr. Lucas D 
Daurelio (Estadística, Facultad de Cs. Bioquímicas y 
Farmacéuticas, UNR) has designed and supervised the 
statistical analysis performed in this work.
RESULTS
Cylindrical shaped BAL for LMOs: Performance without 
biological component 
As was formerly explained, the first BAL constructed 
in our laboratory was designed to house hepatocyte 
suspensions as the biological component and showed 
a good performance[4]. In order to evaluate the use 
of LMOs as alternative biocomponent of our BAL 
prototype, we first studied their viability and functio-
nality in a simpler model, the NRS, as shown in Figure 
725 October 27, 2018|Volume 10|Issue 10|WJH|www.wjgnet.com
2A[5]. Once was established, their ability to metabolize 
ammonia (detoxification of 35.1% ± 7.0 %, or 14.3 ± 
3.6 µmol/g wet tissue, after 120 min incubation, n = 6), 
we modified the cylindrical BAL, originally designed to 
contain hepatocytes, in order to accommodate LMOs 
on its BC.
The cylindrical shaped BAL for LMOs is shown in 
Figure 2B. The hollow fiber cartridge configuration is 
maintained: blood circulates inside the fibers and LMOs 
are placed in the compartment delimited between 
the plastic receptacle and the fiber outer surfaces, 
but this BC has a larger capacity (50 cm3 vs 9 cm3 in 
the previous model). Also, a bigger loading port (Lp 
in Figure 2B) was assembled to the plastic cartridge. 
Both, Lp and BC capacity are larger than in the original 
BAL[4] to allow easy LMO loading and retrieval, and 
to accommodate the biological material, respectively. 
In both designs, approximately 140 hollow fibers are 
aligned inside the cartridge connected to two Y-shaped 
connectors.
We studied the functioning of the device and the 
perfusion system in experiments without a biological 
component. The values obtained for the different 
parameters assayed can be seen in Table 3 (n = 6 
independent runs). Hematocrit values and osmolality 
ratios remained stable during the 120 min of perfusion 
and, though there was an increment in the percentage 
of hemolysis, it was minimal. Ammonia and glucose 
could readily cross the fiber walls because their 
concentrations in both compartments evened out after 
120 min. Total ammonia mass (QNH4+) did not change 
during experiments.
Cylindrical shaped BAL: performance with LMOs as a 
biological component
After determining that the BAL was functioning cor-
rectly without a biological component, the modified 
device was tested with LMOs to establish its capacity 
to keep these tissue slices functional and viable for 120 
min of perfusion.
As a viability parameter, we assayed the release of 
the cytosolic enzyme LDH. The values measured for 
LMOs in the BAL prototype are shown in Table 4 (n = 
6 independent LMO preparations in separate runs), 
compared to the values obtained in the NRS[5] (n = 6 
different LMO preparations). In our BAL, the amount 
of LDH release increased with perfusion time. A similar 
pattern was observed in the NRS and no difference 
was detected when both systems were compared, 
reaching almost the same percentages after 120 min 
(14.7% ± 3.1% for the BAL prototype and 15.5% ± 
3.2% for the NRS).
Respiratory activity determination constitutes a very 
specific metabolic test to evaluate tissue functionality 
and notice the existence of hidden damages[26]. LMOs 
were taken out at different times and put into an 
oxygen chamber to test their oxygen consumption 
capacity (Table 4, n = 6 LMOs taken at each time, 
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coming from different preparations in independent 
BAL-runs/NRS-incubations). This parameter remained 
stable during the 120 min of perfusion in the BAL 
and again no difference was observed compared to 
the NRS, even though in this system there was a sig-
nificant decrease at 60 min and 120 min compared to 
the initial value.
Any biological component employed in a BAL must 
face and deal with the high levels of ammonia in 
the blood of the patients to be treated because the 
accumulation of this metabolite is associated with 
the progression of hepatic failure[3]. Therefore, we 
analyzed different parameters related to ammonia 
metabolism in LMOs. Relative gene expression and 
activity of CPSI and OTC, two key enzymes of the urea 
726 October 27, 2018|Volume 10|Issue 10|WJH|www.wjgnet.com
cycle, were studied and the results obtained are shown 
in Tables 5 and 6 (n = 3 different LMO preparations 
in independent BAL-runs/NRS-incubations). The 
levels of mRNA and activity for both enzymes did not 
significantly change after 120 min of perfusion in the 
BAL prototype. In addition, there were no significant 
differences in the levels measured for LMOs in the 
NRS[5], indicating proper enzyme quantities to perform 
ammonia detoxification. However, despite all these 
similarities, when the LMOs were used as the biological 
component of the cylindrical shaped BAL they were 
unable to metabolize ammonia (Table 7), while in 
the NRS they detoxified 22.2% ± 5.5% and 35.1% 
± 7.0% of the initial dose after 60 min and 120 min, 
respectively (n = 6 different LMO preparations).
1The cylindrical bio-artificial liver designed for liver microorgans functioning without any biological component. B: Blood; BC: Biological compartment; Ht: 
Hematocrit.
aP < 0.05, different from other times; cP < 0.05, different from time 0. BAL: Bio-artificial liver; NRS: Normothermic Reoxygenation System; LDH: Lactate 
dehydrogenase.
BAL: Bio-artificial liver; NRS: Normothermic Reoxygenation System; Cps1: Carbamyl phosphate synthetase Ⅰ; Otc: Ornithine transcarbamylase.
CPSI: Carbamyl phosphate synthetase Ⅰ; OTC: Ornithine transcarbamylase; BAL: Bio-artificial liver; NRS: Normothermic Reoxygenation System.
Table 3  Functional parameters of the cylindrical shaped bio-artificial liver1 (n  = 6 independent runs)
Perfusion time OsmB/OsmBC Ht (%) Hemolysis (%) [Glucose]B/[Glucose]BC [NH4+]B/[NH4+]BC QNH4+ (µmol)
0 min 0.95 ± 0.05 43 ± 3 0.12 ± 0.06 0.12 ± 0.01 23.2 ± 1.2 31.1 ± 3.9
60 min 0.99 ± 0.01 42 ± 6 0.30 ± 0.08 0.81 ± 0.03   1.4 ± 0.4 31.1 ± 4.2
120 min 1.00 ± 0.01 38 ± 2 0.65 ± 0.10 0.94 ± 0.02   1.2 ± 0.2 31.3 ± 3.8
Table 4  Viability and functional parameters evaluated for liver microorgans in the cylindrical shaped bio-artificial liver and the 
Normothermic Reoxygenation System (n  = 6 different liver microorgan preparations in independent bio-artificial liver runs/
Normothermic Reoxygenation System incubations)
Evaluated parameters LDH release (%) Oxygen Consumption (µmol/min·g wet tissue)
Time (min) 0 60 120 0 60 120
Model
Cylindrical BAL 1.9 ± 0.9 9.4 ± 3.0a 14.7 ± 3.1a 1.21 ± 0.24 1.15 ± 0.20 1.16 ± 0.21
NRS 2.6 ± 0.1 8.3 ± 1.2a 15.5 ± 3.2a 1.13 ± 0.11  0.85 ± 0.15c  0.84 ± 0.15c
Table 5  Relative gene expression of Cps1  and Otc  for liver microorgans in the cylindrical shaped bio-artificial liver and the 
Normothermic Reoxygenation System (n  = 3 different liver microorgan preparations in independent bio-artificial liver runs/ 
Normothermic Reoxygenation System incubations)
Relative gene expression Cps1 Otc
Time (min) 0 60 120 0 60 120
Model
Cylindrical BAL 1.05 ± 0.17 0.84 ± 0.09 0.63 ± 0.12 1.02 ± 0.26 0.87 ± 0.21 0.67 ± 0.20
NRS 1.00 ± 0.24 0.96 ± 0.12 0.86 ± 0.10 1.00 ± 0.20 0.87 ± 0.16 0.82 ± 0.07
Table 6  Carbamyl phosphate synthetase Ⅰ and ornithine transcarbamylase enzymatic activity in the cylindrical shaped bio-artificial 
liver and the Normothermic Reoxygenation System (n  = 3 different liver microorgan preparations in independent bio-artificial liver 
runs/Normothermic Reoxygenation System incubations)
Enzymatic activity CPSI (U/g wet tissue) OTC (U/g wet tissue)
Time (min) 0 60 120 0 60 120
Model
Cylindrical BAL 2.48 ± 0.62 2.72 ± 0.61 3.03 ± 0.86 241.7 ± 12.6 235.1 ± 11.9 222.0 ± 23.5
NRS 2.47 ± 0.60 2.82 ± 0.76 3.12 ± 0.73 209.7 ± 33.2 251.8 ± 29.4 228.8 ± 32.8
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Table 7  Ammonia detoxification capacity (µmol/g wet tissue) 
for fresh liver microorgans and hepatocyte suspensions used 
as biological component of the “flat bottom” and cylindrical 
bio-artificial livers (n  = 6 different liver microorgan/
hepatocyte preparations in independent runs)
Cylindrical vs “flat bottom” shaped BAL prototypes: The 
importance of architecture
We hypothesized that the LMOs were unable to 
metabolize ammonia in the cylindrical shaped device 
was not related to the biological component because 
all the other functionality and viability parameters were 
similar to the NRS. Therefore, the problem could be 
due to the artificial part of the device, specifically the 
BC. To test this hypothesis, we decided to change the 
BC architecture of our BAL and mimic the configuration 
and disposition of the LMOs in the NRS (Figure 2A). 
The result was the design of a BAL prototype with a 
completely different shaped BC: The “flat bottom” BAL 
displayed in Figure 2C. Instead of using a cylindrical 
plastic cartridge, we utilized a 25 cm2 culture flask 
that offers a flat base BC where LMOs adopt a similar 
distribution as the one in the NRS. All the other 
components and materials utilized were the same in 
both devices, including the perfusion system. This “flat 
bottom” BAL performed well in experiments without a 
biological component[15].
Ammonia detoxification was the key task that 
LMOs could not perform in the cylindrical shape BAL. 
When they were evaluated in the “flat bottom” BAL, 
fresh LMOs were able to metabolize 32.1% ± 2.2% 
and 49.3% ± 8.8% of the initial NH4+ dose at 60 
min and 120 min, respectively (n = 6 different LMO 
preparations in independent runs)[15], results that 
support the importance of architecture.
According to the results, the devices designed 
in our laboratory could be successfully incorporated 
into BAL systems depending on the chosen biological 
component. In Table 7, we compare both ammonia 
detoxification capacities between LMOs in the “flat 
bottom” and cylindrical BAL prototypes as well as with 
hepatocyte suspensions in our previous cylindrical 
BAL (n = 6 different LMO/hepatocyte preparations in 
independent runs). For the purpose of comparison 
between the different biological components (LMOs 
vs hepatocytes), we performed calculations using the 
following equivalence: 128 × 106 hepatocytes = 1 g of 
liver[27–29]. After 60 min of perfusion, LMOs in the “flat 
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bottom” BAL showed a significantly decreased level of 
ammonia detoxification compared to hepatocytes in 
the cylindrical model (Table 7). However, after 120 min 
both models had similar metabolizing capacities. Rat 
hepatocyte isolation and incubation in the cylindrical 
BAL were performed as already reported by our group[4] 
(routine protocol for hepatocyte isolation is shown in 
Figure S1; and cylindrical BAL operation in Figure S2).
DISCUSSION
The first step before using LMOs in our BAL device 
was the adaptation of the prototype designed for 
hepatocytes, and testing it without any biological 
components. The results obtained (Table 3) demon-
strated a proper exchange of fluids between the blood 
and the BC since the relationship between osmolality 
and the hematocrit values remained stable during 
the 120 min of perfusion. Also, it can be appreciated 
that solute transport functioned properly in both 
directions: ammonia diffused from blood to the extra-
fiber fluid, while glucose flowed the opposite way, 
almost matching their concentrations during the initial 
hour (Table 3). We did not detect unspecific loss of 
ammonia or interaction with any part of the device 
(QNH4+ remained constant) and the small percentage 
of hemolysis measured can be attributed to the action 
of the peristaltic pump. Taken together, the results 
showed that the cylindrical shaped device made in 
our laboratory, with its simple design, could be easily 
adapted and scaled up, which is a very important 
issue in the construction of a BAL intended for clinical 
application.
After corroborating the proper functioning of the 
device, we performed several experiments with LMOs 
as its biological component. The results of these tests 
were unexpected: LMOs showed satisfactory viability 
levels (assayed by LDH release), oxygen consumption 
capacity did not change during the perfusion, and 
conserved levels of transcripts and adequate enzymatic 
activities of CPSI and OTC, but they were not able to 
metabolize ammonia in a significant amount. Even 
more astonishing was the fact that all the assayed 
parameters showed similar values to the ones de-
termined in the NRS[5], where LMOs could detoxify 
35.1% ± 7.0% of the initial 1 mmol/L NH4+ dose after 
120 min.
When adapting the cylindrical BAL model to house 
LMOs as a biological component, we found that, in spite 
of the shaking applied, LMOs piled up over each other 
at the bottom of the cartridge in an array that could 
prevent the correct exchange of nutrients, oxygen, and 
metabolites. Furthermore, the experiments in the NRS 
were accomplished in flat wells in 6-well multi dishes. 
Then, we came up with the idea of mimicking the NRS 
configuration, and developed a BAL prototype with 
a flat surface BC. We reasoned that this geometrical 
disposition would allow LMOs to adopt a looser, not 
aP < 0.05, different from hepatocytes at time 60 min. 128 × 106 hepatocytes 
= 1 g of liver. ND: Not detectable, means that the total ammonia mass 
remained equivalent to the 100% of initial dose at the indicated times; 
LMO: Liver microorgan; BAL: Bio-artificial liver.
Time (min)
Ammonia detoxification capacity (µmol/g wet tissue)
Flat bottom BAL Cylindrical BAL
LMOs LMOs Hepatocytes
60    8.1 ± 1.2a ND 12.5 ± 1.8
120 13.2 ± 2.2 ND 18.6 ± 4.9
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which are obtained by a low-cost technique that is 
easily learned. Also, the required biological material 
could be obtained from donor livers not acceptable 
for transplantation but meeting the criteria to obtain 
adequate pieces to feed this kind of BAL and possibly 
used in multiple treatments. Therefore, pre-assembled 
BALs could be filled with LMOs obtained in the same 
center where they will be immediately applied. The 
prototype we are presenting in this work is constructed 
with standard laboratory and medical supplies, and we 
envisage that they could be constructed at reasonable 
costs and, consequently, commercialized at reasonable 
prices.
After publishing our previous results[15], we became 
aware that it is difficult to predict the conditions needed 
for good performance of the devices based on rational 
design and, instead, much of the experience we have 
accumulated over the years mostly originated by 
trial and error. Especially in this field of BAL research, 
every laboratory seems to apply different strategies 
to achieve the objective of extracorporeal treatment 
of liver failure. Although some basic principles and 
features are followed by all of us, there seems to really 
exist one different BAL for each group of work[31,32]. As 
far as we know, this is the first time that a comparison 
of the same biological component applied to different 
configurations of BALs is reported. In the literature, we 
have always found comparisons of different BALs only 
in review articles that use data from different research 
groups, which renders the analysis incomplete and 
inadequate. However, we have made comparisons in 
the same set of experiments using cells and tissues 
from the same brood of experimental animals, same 
batches of solutions, same laboratory instruments, etc. 
These conditions render our results coherent and valid, 
and strongly demonstrate that architecture of BALs 
can determine the success of this kind of device.
Further investigations must be done in order 
to bring these types of devices to the clinic. Very 
few clinical trials have been performed, and they 
are typically carried out on patients with advanced 
deterioration[32–35]. In conclusion, we demonstrate 
the importance of adapting the artificial component 
architecture to the biological component characteristics 
to obtain an adequate BAL performance regarding 
blood ammonia detoxification.
ARTICLE HIGHLIGHTS
Research background
Liver failure is a condition that usually requires liver transplantation, but in 
some cases acute liver failure resolves spontaneously due to the viable hepatic 
mass remaining after the cause of the damage has disappeared. If the amount 
of this functional tissue has the sufficient capacity to handle the detoxification 
of harmful metabolites produced by the insult and to provide the needed 
essential hepatic molecules and factors, then the regeneration capacity of the 
organ allows the recovery. This is why many attempts have been pursued to 
help the patient´s liver to pass through this acute failure and either recover or 
extend the time frame for a liver transplantation. Artificial livers, either dialysis 
based or incorporating hepatic cells and tissues (these later referred to as bio-
stacked distribution that would benefit the exchange 
mechanisms between LMOs and the bathing media. 
In this way, provided that the volume of the BC is 
equivalent to that of the previous prototype (50 cm3), 
this flat bottomed device offers a surface that allows 
an enhanced bathing and shaking of plane LMOs due 
to their better distribution.
When we tested fresh LMO ammonia detoxification 
efficiency in this new “flat bottom” BAL, the results 
obtained supported our hypothesis. They were able 
to detoxify 49.3% ± 8.8% of the initial ammonia 
overload after 120 min of perfusion[15], contrary to 
the LMOs applied to the cylindrical BAL (Table 7). 
This observation demonstrates the importance of 
adjusting the architecture and design of the artificial 
compartment to a given biological component in order 
to obtain an optimal BAL performance. Although 
we cannot rule out other factors influencing LMO 
detoxification activities that remained unnoticed, the 
only change between the cylindrical and flat bottom 
BALs was the shape of the BC. The BC volume, 
shaking speed, blood flow velocity, oxygen tension, 
and the brand of fibers used in their construction were 
identical.
Both systems published, i.e., the cylindrical 
one operating with isolated hepatocytes[4] and the 
“flat bottom” one operating with LMOs[15], function 
satisfactorily in relation to ammonia detoxification 
(Table 7) and, according to the needs of the patient, 
could be optionally selected in the future. The device 
could also be used as a suitable mini-bioreactor to 
analyze drug toxicity or other parameters of interest. 
We are performing further studies to establish the 
synthetic capacity of the biological components in our 
prototypes.
At present no BAL is in use to clinically treat liver 
failure. Some clinical trials have been conducted (for 
an updated review consult the work of Sakiyama et 
al[30] and references therein) with some success. All 
of these devices use isolated liver-derived cells. Four 
of them use porcine primary hepatocytes either fresh 
(named LSS, Excorp Medical BLSS and AMC-BAL) or 
cryopreserved and microcarrier attached (HepatAssit), 
one uses human primary hepatocytes (MELS), and 
one uses HepG2/C3A cell line (Vitagen ELAD). These 
devices have not become mainstream in clinical 
settings yet because of the complexity of isolating 
hepatocytes and the difficulties for maintaining the 
viability of these cells viable for prolonged periods of 
time. This limits the assembly and transport of the 
devices and confines its use to the centers where 
they were developed. An exception to this could be 
the ELAD system that uses a cell line, but the costs 
of producing the required amount of cellular material 
makes it expensive. It is also limited to places with 
the facilities and expertise to conduct cell culture at a 
large scale. In this sense our BAL prototype, although 
it needs further testing, requires hand-cut LMOs, 
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artificial livers or BALs), are extracorporeal devices intended to aid the failing 
livers to overcome failure or at least to permit the patient to improve to undergo 
transplantation. In this sense, BALs are considered the choice to accomplish 
this job but until now they have been applied only by medical care teams that 
are able to obtain the biological component and to assemble the device at the 
same location making the practice limited to very few centers in the world.
Research motivation
The BAL research field is several decades old but still no successful device has 
been developed. Several prototypes have been submitted to clinical trials but 
none are routinely used in clinical settings or commercially available. These 
prototypes use isolated cells of hepatic origin (isolated primary human or pig 
hepatocytes and HepG2/C3A cell line), which is a biological material that 
requires expertise and money to be obtained and/or maintained. Additionally, 
cryopreservation of primary hepatocytes is not a very successful technique 
and recovery after thawing is poor. Among other researchers in the field, we 
propose and are testing the use of liver microorgans (LMOs) as the biological 
component for BAL devices, which are promising in terms of bearing all hepatic 
cellular types and microarchitecture and involve a simple method to obtain. 
These characteristics are appealing because they bring the possibility of using 
procured organs not suitable for transplantation to get the material necessary 
to feed pre-assembled cartridges at the same centers were the BAL would be 
needed. Our experience in the field has taught us that changes in the artificial 
part of these devices can have an impact on the biological component function. 
The finding that these changes in design, that can be minor or significant, 
have an influence on performance with effects ranging from subtle to massive, 
address the importance of finely tuning the interplay between the components 
of the device to optimize BAL operation.
Research objectives
LMOs failed to detoxify ammonia in a scaled-up BAL configuration that was 
previously successful. We set out to solve this problem and analyze the 
possible reasons of the phenomenon we were observing.
Research methods
The methodology used is the standard in our laboratory and has been 
previously published. The novelty is to perform and report the comparison of 
different BAL designs using the same biological component. This is the first 
report making such a comparison in the same set of experiments using cells 
and tissues from the same brood of experimental animals, same batches 
of solutions, same laboratory instruments, same materials to construct the 
devices, and so forth. 
Research results
The main result we achieved in this work is that LMOs were totally incompetent 
to detoxify ammonia when placed in a cylindrical shaped BAL while they were 
fully able to detoxify ammonia inside a flat bottomed BAL. 
Research conclusions
The accumulation of high levels of ammonia in the blood is an important issue 
in patients presenting liver failure, and is of the highest interest when studying 
this kind of device. In the literature, we have always found comparisons of 
different BALs only in review articles that use data from different research 
groups, which renders the comparative analysis incomplete. Our experimental 
design makes our comparison coherent and valid, and strongly demonstrates 
that the architecture of BALs can determine the success of this kind of device.
Research perspectives
We consider that this is an especially important finding, particularly in the light 
of the results presented, compelling future research to put an effort to finely 
tune the interplay between the artificial and biological components of BALs in 
order to achieve optimal performance and finally reach the clinical setting.
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